Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (48)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Wise, R.
Right arrow Articles by Ashby, J. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wise, R.
Right arrow Articles by Ashby, J. P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy, Vol 42, 721-728, Copyright © 1998 by The British Society for Antimicrobial Chemotherapy

The in-vitro activity of linezolid (U-100766) and tentative breakpoints [In Process Citation]

R Wise, JM Andrews, FJ Boswell and JP Ashby
Department of Medical Microbiology, City Hospital NHS Trust, Birmingham, UK.

The in-vitro activity of linezolid, a novel oxazolidinone, was investigated in comparison with those of amoxycillin, cefuroxime, quinupristin/dalfopristin, trovafloxacin and vancomycin against 420 recent Gram-positive and anaerobic clinical isolates. Linezolid was equally active (MIC90 1 mg/L) against methicillin-susceptible and - resistant Staphylococcus aureus. It demonstrated uniform activity against streptococci and enterococci and no cross-resistance with other agents. The time-kill kinetic data demonstrated that the in-vitro activity of linezolid was predominantly bacteriostatic; slow bactericidal activity was only observed at the higher concentration with streptococci. An increase in inoculum from 10(4) to 10(6) cfu on selected strains had little effect on the MICs (MIC90 within one dilution step) of linezolid and an increase in inoculum from 10(5) to 10(7) cfu/mL had no notable effect on the in-vitro bactericidal activity. A tentative linezolid breakpoint of 2 mg/L was chosen after analysis of distribution of susceptibilities.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
R. Beer, K. W. Engelhardt, B. Pfausler, G. Broessner, R. Helbok, P. Lackner, C. Brenneis, S. T. Kaehler, A. Georgopoulos, and E. Schmutzhard
Pharmacokinetics of Intravenous Linezolid in Cerebrospinal Fluid and Plasma in Neurointensive Care Patients with Staphylococcal Ventriculitis Associated with External Ventricular Drains
Antimicrob. Agents Chemother., January 1, 2007; 51(1): 379 - 382.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
G. Athanassopoulos, A. Pefanis, V. Sakka, D. Iliopoulos, D. Perrea, and H. Giamarellou
Linezolid in Prophylaxis against Experimental Aortic Valve Endocarditis Due to Streptococcus oralis or Enterococcus faecalis
Antimicrob. Agents Chemother., February 1, 2006; 50(2): 654 - 657.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
B. Meyer, G. V. Kornek, M. Nikfardjam, G. D. Karth, G. Heinz, G. J. Locker, W. Jaeger, and F. Thalhammer
Multiple-dose pharmacokinetics of linezolid during continuous venovenous haemofiltration
J. Antimicrob. Chemother., July 1, 2005; 56(1): 172 - 179.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
D. K Farver, D. D Hedge, and S. C Lee
Ramoplanin: A Lipoglycodepsipeptide Antibiotic
Ann. Pharmacother., May 1, 2005; 39(5): 863 - 868.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
L. M. Ednie, A. Rattan, M. R. Jacobs, and P. C. Appelbaum
Antianaerobe Activity of RBX 7644 (Ranbezolid), a New Oxazolidinone, Compared with Those of Eight Other Agents
Antimicrob. Agents Chemother., March 1, 2003; 47(3): 1143 - 1147.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
G. Ackermann, D. Adler, and A. C. Rodloff
In vitro activity of linezolid against Clostridium difficile
J. Antimicrob. Chemother., March 1, 2003; 51(3): 743 - 745.
[Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
A. M. Lovering, J. Zhang, G. C. Bannister, B. J. A. Lankester, J. H. M. Brown, G. Narendra, and A. P. MacGowan
Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement
J. Antimicrob. Chemother., July 1, 2002; 50(1): 73 - 77.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
M. Peric, G. Lin, C. L. Clark, M. R. Jacobs, and P. C. Appelbaum
Antipneumococcal activity of AZD2563, a new oxazolidinone, compared with nine other agents
J. Antimicrob. Chemother., July 1, 2002; 50(1): 95 - 100.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
L. M. Ednie, M. R. Jacobs, and P. C. Appelbaum
Anti-anaerobic activity of AZD2563, a new oxazolidinone, compared with eight other agents
J. Antimicrob. Chemother., July 1, 2002; 50(1): 101 - 105.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
J. A. Karlowsky, L. J. Kelly, I. A. Critchley, M. E. Jones, C. Thornsberry, and D. F. Sahm
Determining Linezolid's Baseline In Vitro Activity in Canada Using Gram-Positive Clinical Isolates Collected prior to Its National Release
Antimicrob. Agents Chemother., June 1, 2002; 46(6): 1989 - 1992.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
A. Gikas, I. Spyridaki, E. Scoulica, A. Psaroulaki, and Y. Tselentis
In Vitro Susceptibility of Coxiella burnetii to Linezolid in Comparison with Its Susceptibilities to Quinolones, Doxycycline, and Clarithromycin
Antimicrob. Agents Chemother., November 1, 2001; 45(11): 3276 - 3278.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
C. G. Gemmell and o. b. o. participating investigators in France, Germany, Ho
Susceptibility of a variety of clinical isolates to linezolid: a European inter-country comparison
J. Antimicrob. Chemother., July 1, 2001; 48(1): 47 - 52.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
W. J. Munckhof, C. Giles, and J. D. Turnidge
Post-antibiotic growth suppression of linezolid against Gram-positive bacteria
J. Antimicrob. Chemother., June 1, 2001; 47(6): 879 - 883.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
T. Gee, R. Ellis, G. Marshall, J. Andrews, J. Ashby, and R. Wise
Pharmacokinetics and Tissue Penetration of Linezolid following Multiple Oral Doses
Antimicrob. Agents Chemother., June 1, 2001; 45(6): 1843 - 1846.
[Abstract] [Full Text]

Home page
 J Antimicrob ChemotherHome page
E. Cercenado, F. Garcia-Garrote, and E. Bouza
In vitro activity of linezolid against multiply resistant Gram-positive clinical isolates
J. Antimicrob. Chemother., January 1, 2001; 47(1): 77 - 81.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
C. Betriu, M. Redondo, M. L. Palau, A. Sánchez, M. Gómez, E. Culebras, A. Boloix, and J. J. Picazo
Comparative In Vitro Activities of Linezolid, Quinupristin-Dalfopristin, Moxifloxacin, and Trovafloxacin against Erythromycin-Susceptible and -Resistant Streptococci
Antimicrob. Agents Chemother., July 1, 2000; 44(7): 1838 - 1841.
[Abstract] [Full Text]

Home page
 J Antimicrob ChemotherHome page
A. P. Johnson, M. Warner, and D. M. Livermore
Activity of linezolid against multi-resistant Gram-positive bacteria from diverse hospitals in the United Kingdom
J. Antimicrob. Chemother., February 1, 2000; 45(2): 225 - 230.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
V. A. Luna and M. C. Roberts
In-vitro activities of 11 antibiotics against 75 strains of Streptococcus pneumoniae with reduced susceptibilities to penicillin isolated from patients in Washington State
J. Antimicrob. Chemother., October 1, 1999; 44(4): 578 - 580.
[Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
S. Miyazaki, Y. Ishii, A. Ohno, N. Furuya, T. Matsumoto, K. Tateda, and K. Yamaguchi
In-vitro activities of 11 antibiotics against vancomycin-resistant enterococci isolated in Japan
J. Antimicrob. Chemother., September 1, 1999; 44(3): 415 - 416.
[Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
R. C. Moellering, P. K. Linden, J. Reinhardt, E. A. Blumberg, F. Bompart, and G.H. Talbot
The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium
J. Antimicrob. Chemother., August 1, 1999; 44(2): 251 - 261.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.